Ceribell, Inc.CBLLEarnings & Financial Report
Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.
Revenue
$20.5M
Gross Profit
$18.0M
Operating Profit
$-14.2M
Net Profit
$-12.8M
Gross Margin
87.9%
Operating Margin
-69.3%
Net Margin
-62.4%
YoY Growth
N/A
EPS
$-0.36
Ceribell, Inc. Q1 FY2025 Financial Summary
Ceribell, Inc. reported revenue of $20.5M for Q1 FY2025, with a net profit of $-12.8M (-62.4% margin). Cost of goods sold was $2.5M, operating expenses totaled $32.2M.
Key Financial Metrics
| Total Revenue | $20.5M |
|---|---|
| Net Profit | $-12.8M |
| Gross Margin | 87.9% |
| Operating Margin | -69.3% |
| Report Period | Q1 FY2025 |
Revenue Breakdown
Ceribell, Inc. Q1 FY2025 revenue of $20.5M breaks down across 2 segments, led by Products at $15.6M (76.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $15.6M | 76.2% |
| Subscription | $4.9M | 23.8% |
Ceribell, Inc. Revenue by Segment — Quarterly Trend
Ceribell, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Subscription) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | $18.8M | $17.0M | $15.9M | $15.6M |
| Subscription | $6.0M | $5.6M | $5.3M | $4.9M |
Ceribell, Inc. Annual Revenue by Year
Ceribell, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $89.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $89.1M |
Ceribell, Inc. Quarterly Revenue & Net Profit History
Ceribell, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $24.8M | — | $-13.5M | -54.6% |
| Q3 FY2025 | $22.6M | +31.4% | $-13.5M | -59.6% |
| Q2 FY2025 | $21.2M | — | $-13.6M | -64.4% |
| Q1 FY2025 | $20.5M | — | $-12.8M | -62.4% |
| Q3 FY2024 | $17.2M | — | $-10.4M | -60.6% |
Income Statement
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Revenue | $17.2M | $20.5M | $21.2M | $22.6M | $24.8M |
| YoY Growth | N/A | N/A | N/A | 31.4% | N/A |
Balance Sheet
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Assets | $47.1M | $213.5M | $207.7M | $199.5M | $195.8M |
| Liabilities | $35.6M | $32.6M | $35.5M | $35.4M | $40.5M |
| Equity | $-136.0M | $180.9M | $172.2M | $164.1M | $155.3M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-11.4M | $-7.5M | $-11.1M | $-10.8M |